Drug intelligence / Profile preview

RESILIENT

Development stage: Preclinical
Lead developer: Children's Hospital, Zhejiang University School of Medicine
Administration: Oral

Overview

RESILIENT is a pharmaceutical drug being investigated for its effectiveness and tolerability in reducing weight in overweight or obese adolescent and pediatric patients. The active substance is referred to as Ruijian, and it is administered twice daily (BID) at doses of 1.5g or 3.0g.

Brand names: RESILIENT
Other names: Ruijian

Beyond the preview

Go deeper on RESILIENT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESILIENT.

Explore the full profile